Galectin-3 Predicts Long-Term Cardiovascular Death in High-Risk Patients with Coronary Artery Disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 3, 2015, Pages 725-732

  Maiolino, Giuseppe ^a   Rossitto, Giacomo ^a   Pedon, Luigi ^d   Cesari, Maurizio ^a   Frigo, Anna Chiara ^b   Azzolini, Matteo ^a   Plebani, Mario ^c   Rossi, Gian Paolo ^a  

^a Department of Medicine DIMED   (Italy)

^b and Vascular Sciences ^*  (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d Divisione di Cardiologia Ospedale di Cittadella   (Italy)

Author keywords

atherosclerosis; coronary artery disease; galectin 3; prognosis; prospective studies

Indexed keywords

DIGOXIN; GALECTIN 3; BIOLOGICAL MARKER; GALECTIN-3, HUMAN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT HISTORY OF CORONARY ANGIOPLASTY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; BLOOD; CHI SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; DISEASE COURSE; EPIDEMIOLOGY; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; INCIDENCE; ITALY; KAPLAN MEIER METHOD; MORTALITY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; RISK ASSESSMENT; RISK FACTOR; STROKE; TIME FACTOR; UPREGULATION;

ACUTE CORONARY SYNDROME; BIOMARKERS; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; GALECTIN 3; HUMANS; INCIDENCE; ITALY; KAPLAN-MEIER ESTIMATE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; STROKE VOLUME; TIME FACTORS; UP-REGULATION; VENTRICULAR FUNCTION, LEFT;

EID: 84921827297     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304964     Document Type: Article

References (36)

1. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K, Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994 76 597 598
2. Wang JL, Gray RM, Haudek KC, Patterson RJ, Nucleocytoplasmic lectins. Biochim Biophys Acta 2004 1673 75 93. doi: 10.1016/j.bbagen.2004.03.013
3. Hughes RC, Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta 1999 1473 172 185
4. Gaudin JC, Mehul B, Hughes RC, Nuclear localisation of wild type and mutant galectin-3 in transfected cells. Biol Cell 2000 92 49 58. doi: 10.1016/S0248-4900(00)88763-8
5. Sano H, Hsu DK, Apgar JR, Yu L, Sharma BB, Kuwabara I, Izui S, Liu FT, Critical role of galectin-3 in phagocytosis by macrophages. J Clin Invest 2003 112 389 397. doi: 10.1172/JCI17592
6. Sano H, Hsu DK, Yu L, Apgar JR, Kuwabara I, Yamanaka T, Hirashima M, Liu FT, Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol 2000 165 2156 2164
7. Arar C, Gaudin JC, Capron L, Legrand A, Galectin-3 gene (LGALS3) expression in experimental atherosclerosis and cultured smooth muscle cells. FEBS Lett 1998 430 307 311
8. Moutsatsos IK, Wade M, Schindler M, Wang JL, Endogenous lectins from cultured cells: nuclear localization of carbohydrate-binding protein 35 in proliferating 3T3 fibroblasts. Proc Natl Acad Sci USA 1987 84 6452 6456
9. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, André S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM, Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004 110 3121 3128. doi: 10.1161/01.CIR.0000147181.65298.4D
10. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM, Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006 48 1217 1224. doi: 10.1016/j.jacc.2006.03.061
11. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ, Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011 43 60 68. doi: 10.3109/07853890.2010.538080
12. Yancy CW, Jessup M, Bozkurt B, 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013 128 e240 327
13. Tsai TH, Sung PH, Chang LT, Sun CK, Yeh KH, Chung SY, Chua S, Chen YL, Wu CJ, Chang HW, Ko SF, Yip HK, Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. J Atheroscler Thromb 2012 19 1073 1082
14. Grandin EW, Jarolim P, Murphy SA, Ritterova L, Cannon CP, Braunwald E, Morrow DA, Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem 2012 58 267 273. doi: 10.1373/clinchem.2011.174359
15. Szadkowska I, Wlazel RN, Migala M, Bajon-Laskowska K, Szadkowski K, Zielińska M, Paradowski M, Pawlicki L, The association between galectin-3 and occurrence of reinfarction early after first myocardial infarction treated invasively. Biomarkers 2013 18 655 659. doi: 10.3109/1354750X.2013.840801
16. Tuñón J, Blanco-Colio L, Cristóbal C, Tarín N, Higueras J, Huelmos A, Alonso J, Egido J, Asensio D, Lorenzo Ó Mahíllo-Fernández I, Rodríguez-Artalejo F, Farré J, Martín-Ventura JL, López-Bescós L, Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease. Am J Cardiol 2014 113 434 440. doi: 10.1016/j.amjcard.2013.10.012
17. Madrigal-Matute J, Lindholt JS, Fernandez-Garcia CE, Benito-Martin A, Burillo E, Zalba G, Beloqui O, Llamas-Granda P, Ortiz A, Egido J, Blanco-Colio LM, Martin-Ventura JL, Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis. J Am Heart Assoc 2014 3 e000785
18. Cesari M, Maiolino G, Colonna S, Zanchetta M, Pedon L, Maiolino P, Pessina AC, Rossi GP, Under treatment with lipid-lowering drugs of high-risk coronary heart disease patients of the GENICA study. J Cardiovasc Pharmacol 2003 42 484 490
19. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, Larson MG, Levy D, Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 2012 60 1249 1256. doi: 10.1016/j.jacc.2012.04.053
20. Falcone C, Lucibello S, Mazzucchelli I, Bozzini S, D'Angelo A, Schirinzi S, Totaro R, Falcone R, Bondesan M, Pelissero G, Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol 2011 24 905 913
21. Nachtigal M, Ghaffar A, Mayer EP, Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am J Pathol 2008 172 247 255. doi: 10.2353/ajpath.2008.070348
22. Nachtigal M, Al-Assaad Z, Mayer EP, Kim K, Monsigny M, Galectin-3 expression in human atherosclerotic lesions. Am J Pathol 1998 152 1199 1208
23. Carrasco-Sánchez FJ, Aramburu-Bodas O, Salamanca-Bautista P, Morales-Rull JL, Galisteo-Almeda L, Páez-Rubio MI, Arias-Jiménez JL, Aguayo-Canela M, Pérez-Calvo JI, Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. Int J Cardiol 2013 169 177 182. doi: 10.1016/j.ijcard.2013.08.081
24. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, Bakker SJ, van der Harst P, The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012 272 55 64. doi: 10.1111/j.1365-2796.2011.02476.x
25. Daniels LB, Clopton P, Laughlin GA, Maisel AS, Barrett-Connor E, Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study. Am Heart J 2014 167 674 82.e1. doi: 10.1016/j.ahj.2013.12.031
26. Maiolino G, Lenzini L, Pedon L, Cesari M, Seccia TM, Frigo AC, Rossitto G, Caroccia B, Rossi GP, Lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms and cardiovascular events in patients with coronary artery disease. J Cardiovasc Med (Hagerstown) 2015 16 29 36. doi: 10.2459/JCM.0000000000000057
27. Maiolino G, Pedon L, Cesari M, Frigo AC, Barisa M, Rossitto G, Seccia TM, Zanchetta M, Rossi GP, Antibodies to malondialdehyde oxidized low-density lipoproteins predict long term cardiovascular mortality in high risk patients. Int J Cardiol 2013 168 484 489. doi: 10.1016/j.ijcard.2012.09.165
28. Rossi GP, Maiolino G, Zanchetta M, Sticchi D, Pedon L, Cesari M, Montemurro D, De Toni R, Zavattiero S, Pessina AC, The T(-786)C endothelial nitric oxide synthase genotype predicts cardiovascular mortality in high-risk patients. J Am Coll Cardiol 2006 48 1166 1174. doi: 10.1016/j.jacc.2006.05.046
29. Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M, Böhm BO, März W, Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 2005 111 980 987. doi: 10.1161/01.CIR.0000156457.35971.C8
30. Ivanes F, Susen S, Mouquet F, Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J 2012 33 191 202. doi: 10.1093/eurheartj/ehr176
31. Motiwala SR, Szymonifka J, Belcher A, Weiner RB, Baggish AL, Sluss P, Gaggin HK, Bhardwaj A, Januzzi JL, Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail 2013 15 1157 1163. doi: 10.1093/eurjhf/hft075
32. Dieplinger B, Egger M, Haltmayer M, Kleber ME, Scharnagl H, Silbernagel G, de Boer RA, Maerz W, Mueller T, Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. Clin Chem 2014 60 530 540. doi: 10.1373/clinchem.2013.209858
33. Rossi GP, Maiolino G, Seccia TM, Burlina A, Zavattiero S, Cesari M, Sticchi D, Pedon L, Zanchetta M, Pessina AC, Hyperhomocysteinemia predicts total and cardiovascular mortality in high-risk women. J Hypertens 2006 24 851 859. doi: 10.1097/01.hjh.0000222754.75196.5c
34. Cesari M, Zanchetta M, Burlina A, Pedon L, Maiolino G, Sticchi D, Pessina AC, Rossi GP, Hyperhomocysteinemia is inversely related with left ventricular ejection fraction and predicts cardiovascular mortality in high-risk coronary artery disease hypertensives. Arterioscler Thromb Vasc Biol 2005 25 115 121. doi: 10.1161/01.ATV.0000149674.62430.e7
35. Wang G, Siow YL, O K, Homocysteine stimulates nuclear factor kappaB activity and monocyte chemoattractant protein-1 expression in vascular smooth-muscle cells: a possible role for protein kinase C. Biochem J 2000 352 Pt 3 817 826
36. Dumic J, Lauc G, Flögel M, Expression of galectin-3 in cells exposed to stress-roles of jun and NF-kappaB. Cell Physiol Biochem 2000 10 149 158. doi: 16345